Compugen Ltd. · NASDAQ:CGEN
Compugen — Technical Presentation (October 2026)
33 slides from Compugen's technical presentation, Oct 5, 2026
Slide 1: Virtual KOL Event on COM701 in Ovarian Cancer & Unigen Platform Update
Virtual KOL Event on COM 7 0 1 in Ovar ian Canc er & Unigen Platform Update October 2026
Slide 2: Safe Harbor Statement
S a fe H a r b o r S tate m e nt This presentation contains “forward-looking statements” within the meaning of the dependent on entering into collaboration agreements with third parties and Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the Compugen may not be succes
Slide 3: Agenda
Agenda Virtual KOL Event | Monday, October 5, 2026 | 8:00 AM ET | Live Webcast Topic Presenter Welcome & Introduction Eran Ophir, Ph.D. President & Chief Executive Officer of Compugen Compugen Overview MAIA-Ovarian: Randomized Adaptive Platform Trial of COM701 in Platinum Sensitive Ovarian Cancer (I
Slide 4: Focus on novel immuno-oncology antibodies discovered by Unigen
Fo c u s o n n ove l i m m u n o - o n c o l o g y a nt i b o d i e s D i s c o v e r e d b y C o m p u g e n ’s c o m p u t a t i o n a l d i s c o v e r y p l a t f o r m - U n i g e n T M Rich clinical pipeline with validating partnerships >$1bn in milestones PLUS royalties Fully-owned Clinical A
Slide 5: Strong biological rationale to target PVRIG in ovarian cancer
S t ro n g b i o l o g i c a l rat i o n a l e to ta rget P V R I G i n o va r i a n c a n c e r • High PVRIG pathway expression levels in ovarian cancer • PVRIG pathway differentially expressed on early differentiated stem like memory T cells and dendritic cells compared to other immune checkpoints
Slide 6: Characterizing PROC responding patients across Phase 1
Yeku et.al. ESMO 2025 C h a ra c te r i z i n g P RO C re s p o n d i n g p at i e nt s a c ro s s P h a s e 1 G u i d e d t h e d e s i g n o f o n g o i n g M A I A - o va r i a n P S O C m a i n t e n a n c e p l a t fo r m t r i a l Patients without liver metastases - Patients derived clinical b
Slide 7: Advancing COM701 to address unmet need in PSOC
A d va n c i n g CO M 7 0 1 to a d d re s s u n m et n e e d i n P S O C Building on data generated in PROC Platinum Sensitive Ovarian Cancer (PSOC) Platinum Resistant Ovarian Cancer (PROC) Platinum free ≥6-month before relapse Platinum free <6-month before relapse Immune system more compromised and
Slide 8: MAIA-ovarian: adaptive trial with maintenance COM701 therapy
M A I A - o va r i a n : a d a p t i ve t r i a l w i t h m a i nte n a n c e CO M 7 0 1 t h e ra p y i n re l a p s e d p l at i n u m s e n s i t i ve o va r i a n c a n c e r Sub-trial 1 Key eligibility Endpoints Single agent activity of COM701 criteria versus placebo (standard of care) Primary:
Slide 9: Evolving Treatment Landscape in Ovarian Cancer
Evolving Treatment Landscape in Ovarian Cancer Oladapo Yeku, MD, PhD, FACP, FASCO Associate Professor of Medicine, Harvard Medical School Director of Translational Research Center for Gynecologic Medical Oncology Massachusetts General Hospital October 5, 2026
Slide 10: A cycle of remission and relapse
OVARIAN CANCER A cycle of remission and relapse 1 2 3 Initial treatment Remission Relapse Some continue on a Surgery and chemotherapy. Treatment resumes. Each maintenance drug. Many do Most patients respond well. remission tends to be shorter. not. Time spent in remission — off chemotherapy — is wha
Slide 11: One interval shapes the next decision
HOW TREATMENT IS CHOSEN One interval shapes the next decision Platinum Free Interval (PFI): Time from the last platinum chemotherapy until the cancer returns Sensitive Resistant PFI over 6 months PFI under 6 months More options Fewer options Platinum sensitivity determines the next treatment and inf
Slide 12: Patients in remission with no treatment options
THE GAP Patients in remission with no treatment options Who they are Current practice Observation • Responded to their most recent chemotherapy Periodic scans, with treatment resuming only at relapse. • Ineligible for, or have exhausted, maintenance options • Still recovering from cumulative toxicit
Slide 13: The maintenance challenge remains
THE LANDSCAPE IN ONE VIEW The maintenance challenge remains • 1st line usage of PARPi and Bev leaves more 2nd and 3rd line patients without maintenance options • ADCs are reshaping treatment, but maintenance still requires tolerable regimens 01 MOMENTUM 02 PAYLOAD CONVERGENCE 03 MAINTENANCE FIT ADCs
Slide 14: Three reasons the setting was selected
RATIONALE FOR MAIA-OVARIAN Three reasons the setting was selected 1 2 3 A distinct immune Early clinical Favorable conditions pathway observations Less compromised immune COM701 acts on a novel Across early CGEN PROC trials system in earlier lines of checkpoint where previous in 60 heavily pre-treat
Slide 15: COM701 as a potential maintenance option
UNMET MEDICAL NEED COM701 as a potential maintenance option 2nd/3rd Line Maintenance Therapy in Platinum Sensitive Ovarian Cancer GOAL Potential for: Extend the duration of platinum sensitivity for Maintaining platinum sensitivity patients in remission with no approved maintenance option. Extending
Slide 16: Questions
(III Questions
Slide 17: From a Validated Discovery Engine to New Opportunities
From a Validated Discovery Engine to New Opportunities Dr. Sharon Kredo-Russo, SVP Research & Discovery October 2026
Slide 18: A Rich Clinical Pipeline. Global Pharma Partnerships
A Rich Clinical Pipeline. Global Pharma Partnerships Early-stage Fully-owned Phase 1 Phase 3 pipeline Clinical Assets licensed to Gilead AstraZeneca program Multiple assets COM701 GS-0321 Rilvegostomig (previously COM503) 1 COM902 1. Compugen responsible for preclinical development and first- in-hum
Slide 19: Behind the Discoveries
Behind the Discoveries: Compugen’s proven AI-powered discovery engine, continuously connecting computational prediction, biological validation and clinical learning. Input >>> Output 19
Slide 20: Expanding Compugen's Target Discovery into Tumor-Associated Antigens
Expanding Compugen’s Target Discovery into Tumor- Associated Antigens (TAAs) TAAs provide the tumor address for targeted therapies, directing immune activity or drug delivery toward cancer cells Tumor-Associated T-cell Engagers (TCEs) Antigen (TAA) Bring T cells into direct contact with tumor cells,
Slide 21: T-cell Engagers Create an Immediate Need for the Right Tumor Targets
T-cell Engagers Create an Immediate Need for the Right Tumor Targets Tumor cell T-cell A Powerful Modality Growing Market Opportunity TCEs trigger potent anti-tumor activity, >$18–20B with growing potential in solid tumors projected market by 2035* T-cell Engager TAAs Direct the Activity (TCE) Few T
Slide 22: A Powerful Therapy Is Only as Good as Its Target
A Powerful Therapy Is Only as Good as Its Target 12 T-cell engager drugs have been approved, validating the therapeutic modality, yet only 2 in solid tumors, where target quality remains a critical constraint Clean profile Tarlatamab - APPROVED Safety profile- Healthy RNA tissue dataset High Mesothe
Slide 23: Expanding Compugen's proven discovery engine in IO to uncover novel TAAs
Expanding Compugen’s proven discovery engine in IO to uncover novel TAAs
Slide 24: AI-Powered Discovery Engine, Built for TAAs
AI-Powered Discovery Engine, Built for TAAs Compugen’s validated AI-powered discovery engine, continuously connecting computational prediction, biological validation and clinical learning Input >>> Output 24
Slide 25: Finding the Right TAAs
Finding the Right TAAs Versatile discovery platform Adapting AI-driven discovery and analysis to each biological challenge Unique multi-omics Deep biological understanding approach Revealing insights across biological layers that no single view can provide Novel target discovery Uncovering novel tar
Slide 26: Search Broadly, Understand Deeply
Search Broadly, Understand Deeply Search Broadly Understand Deeply A rich biological A multidimensional landscape for discovery target profile > 50K Patient > 100M Tumor population Samples across Single cells specificity coverage >1000 IO datasets >3,700 21 Intratumoral Safety – Normal Tumor & norma
Slide 27: From Biological Evidence to Informed TAA Selection
From Biological Evidence to Informed TAA Selection Integrating multiple biological layers into explainable, multidimensional target scores Predicted Safety and Efficacy Profiles Transparent Colorectal cancer scoring system Identify targets with potential better profile than benchmarks 27
Slide 28: Multi-Omics Evidence Supports Differentiated TAA Candidates
Multi-Omics Evidence Supports Differentiated TAA Candidates Safety- Healthy and cancer tissue Protein confirmation Expression Tumor- Cell-type specificity & coverage IHC Maps tissue localization & tumor specificity 1 Converging evidence builds confidence in the target differentiated biological profi
Slide 29: Target Pairs Expand the TAA Discovery Opportunity
Target Pairs Expand the TAA Discovery Opportunity Some therapeutic challenges may be addressed more effectively through paired-target approaches AND Gating OR Gating Sparing the healthy cells Broaden tumor coverage T cell T cell T cell CD3 AND Target A Target B Target C OR Target D Tumor Tumor Tumor
Slide 30: Target Pairs Expand the TAA Discovery Opportunity
Target Pairs Expand the TAA Discovery Opportunity AND Gating OR Gating Improve tumor selectivity- example from colorectal cancer Broaden tumor coverage- example from prostate cancer Target A Target C Target B Target D Target A and B Target C or D expands TAA discovery from individual targets to comp
Slide 31: One Discovery Engine, Broader IO Opportunities
One Discovery Engine, Broader IO Opportunities Input >>> Output Input >>> Output Input Output >>> A validated foundation Expanding into a new high-value frontier Novel IO Target Discovery Novel Target Discovery in Targeted Immune Activation Discovering previously unrecognized IO targets and Expandin
Slide 32: Multiple Potential Paths to Value
Multiple Potential Paths to Value Discovery of Enable Leverage of multiple assets partnerships internal pipeline Novel TAA-driven Collaborations Potential combinations therapeutics across across discovery and with Compugen’s solid-tumor indications development current programs 32
Slide 33: Validated Discovery Engine. Expanded Possibilities.
Validated Discovery Engine. Expanded Possibilities. Compugen expands its validated discovery engine through UnigenX , creating complementary opportunities across immuno-oncology. Thank you www.cgen.com 33